Tag: a clinical-stage biotechnology company commercializing a novel vaccination platform
Vaxxas raises $34 million to clinically advance needle-free vaccines, including a next-generation COVID-19 vaccine...
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has announced it has completed a financing round which raised US$23 million (A$34 million) in new funds.
Featured Article
Behind the Australian Made logo: Six manufacturers shaping local industry
Australian manufacturers are continuing to invest in local production, innovation and sustainability across a wide range of industries. From textiles and packaging to construction and advanced manufacturing, Australian Made licensees are developing products tailored to local conditions while supporting Australian jobs and capabilities.
